Herve Avet-Loiseau

Herve Avet-Loiseau

UNVERIFIED PROFILE

Are you Herve Avet-Loiseau?   Register this Author

Register author
Herve Avet-Loiseau

Herve Avet-Loiseau

Publications by authors named "Herve Avet-Loiseau"

Are you Herve Avet-Loiseau?   Register this Author

100Publications

5172Reads

28Profile Views

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Leukemia 2019 Sep 9;33(9):2324-2330. Epub 2019 Apr 9.

ProfilExpert, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0452-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756025PMC
September 2019

Monoclonal Gammopathy May Be of Unpredictable Significance.

JAMA Oncol 2019 Jul 18. Epub 2019 Jul 18.

Genomics of Myeloma Laboratory, L'Institut Universitaire du Cancer Oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.1580DOI Listing
July 2019

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

Leukemia 2019 Jun 10. Epub 2019 Jun 10.

Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0498-5DOI Listing
June 2019

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2019 May 29;19(5):e228-e237. Epub 2019 Jan 29.

Department of Biochemistry, University Hospital of Nantes, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.007DOI Listing
May 2019

Multiple myeloma immunophenotyping: method validation.

Ann Biol Clin (Paris) 2019 Apr;77(2):197-217

IUC-T laboratoire d'hématologie, CHU de Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/abc.2019.1426DOI Listing
April 2019

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements.

Leukemia 2019 02 20;33(2):313-318. Epub 2018 Dec 20.

Institut Universitaire du Cancer, CHU, Centre de Recherche en Cancérologie de Toulouse, INSERM, 1037, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0339-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365491PMC
February 2019

Introduction to a review series on advances in multiple myeloma.

Blood 2019 02 26;133(7):621. Epub 2018 Dec 26.

Associate Editor, Blood.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-877795DOI Listing
February 2019

Risk-Based Therapeutic Strategies.

Cancer J 2019 Jan/Feb;25(1):54-58

From the IUC-Oncopole and CRCT INSERM U1037, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000352DOI Listing
January 2019

Multiple myeloma clonal evolution in homogeneously treated patients.

Leukemia 2018 12 12;32(12):2636-2647. Epub 2018 Jun 12.

IUC-Oncopole, and CRCT INSERM U1037, 31100, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0153-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603429PMC
December 2018

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14).

Blood 2018 12 14;132(26):2778-2780. Epub 2018 Nov 14.

Unit for Genomics in Myeloma, Institut Universitaire du Cancer-Oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-876433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307986PMC
December 2018

DKK1 and sclerostin are early markers of relapse in multiple myeloma.

Bone 2018 08 6;113:114-117. Epub 2017 Oct 6.

Centre de rhumatologie, Hopital Purpan, 1 place du docteur Joseph Baylac, 31300 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2017.10.004DOI Listing
August 2018

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.

Leukemia 2018 06 28;32(6):1267-1276. Epub 2018 Mar 28.

Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0098-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990526PMC
June 2018

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.

Am Soc Clin Oncol Educ Book 2018 May;38:675-680

From the Hematology Department, University Hospital, Nancy, France; Myeloma Genomics Laboratory, University Hospital, Toulouse, France; and Myeloma Genomics Laboratory, University Hospital, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200879DOI Listing
May 2018

Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.

Cancer Cell 2018 04;33(4):634-648.e5

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, 4006 QLD, Australia; School of Medicine, University of Queensland, St Lucia 4006 QLD, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.02.007DOI Listing
April 2018

Optimizing therapy for del(17p) multiple myeloma.

Oncotarget 2017 Dec 6;8(66):109859-109860. Epub 2017 Dec 6.

University Cancer Center of Toulouse Institut National de la Santé, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746348PMC
December 2017

[Circulating exosomal microRNA as biomarkers in mutiple myeloma].

Med Sci (Paris) 2017 Nov 4;33(11):939-941. Epub 2017 Dec 4.

Institut universitaire du cancer Oncopole, avenue Hubert Curien, 31100 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/20173311008DOI Listing
November 2017

Minimal Residual Disease Negativity Is a New End Point of Myeloma Therapy.

J Clin Oncol 2017 09 19;35(25):2863-2865. Epub 2017 May 19.

Jean-Luc Harousseau, Groupe Confluent, Nantes, France; and Herve Avet-Loiseau, Institut Universitaire du Cancer Oncopole, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.1331DOI Listing
September 2017

Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

J Clin Oncol 2017 Sep 7;35(25):2911-2918. Epub 2017 Jul 7.

Philippe Moreau, Florence Caillon, Caroline Bodet-Milin, Aurelie Gaultier, Jean-Michel Nguyen, Benoit Dupas, Eric Frampas, and Françoise Kraeber-Bodere, University Hospital, Nantes; Michel Attal, University Hospital, Toulouse; Denis Caillot, University Hospital, Dijon; Margaret Macro, University Hospital, Caen; Lionel Karlin, University Hospital, Lyon; Laurent Garderet, University Hospital Saint-Antoine, Paris; Thierry Facon, University Hospital, Lille; Lotfi Benboubker, University Hospital, Tours; Martine Escoffre-Barbe, University Hospital, Rennes; Anne-Marie Stoppa, Institut Paoli-Calmettes, Marseille; Kamel Laribi, University Hospital, Le Mans; Cyrille Hulin and Gerald Marit, University Hospital, Bordeaux; Aurore Perrot, University Hospital, Nancy; Jean-Richard Eveillard, University Hospital, Brest; Brigitte Pegourie, University Hospital, Grenoble; Veronique Dorvaux, University Hospital, Metz; Carine Chaleteix, University Hospital, Clermont-Ferrand; and Herve Avet-Loiseau, University Hospital, Toulouse, France; and Kenneth Anderson, Paul Richardson, and Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.2975DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578392PMC
September 2017

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

N Engl J Med 2017 04;376(14):1311-1320

From the Institut Universitaire du Cancer de Toulouse-Oncopole (M.A., M.R., C.P., S.R., H.A.-L.) and Service d'Epidémiologie, Centre Hospitalier et Universitaire de Toulouse (V.L.-C.), Toulouse, Hôpital Haut-Lévêque, Bordeaux Pessac (C.H.), Centre Hospitalier et Universitaire la Miletrie, Poitiers (X.L.), Centre Hospitalier Le Bocage, Dijon (D.C.), Centre Hospitalier et Universitaire de Rennes, Rennes (M.E.), Hôpital St.-Louis (B.A., J.P.F.), Centre Hospitalier Universitaire, Hôpital St.-Antoine (L.G.), Institut Curie (C.M.), and Haute Autorité de Santé (J.-L.H.), Paris, Institut d'Hématologie de Basse Normandie, Centre Hospitalier et Universitaire de Caen, Caen (M.M.), Centre Hospitalier et Universitaire Henri Mondor, Creteil (K.B.), Hôpital Claude Huriez, Lille (T.F.), and Hôtel Dieu, Nantes (P.M.) - all in France; Institut Jules Bordet, Brussels (N. Meuleman); and Dana-Farber Cancer Institute, Boston (M.E.M., A.A.Z., E.A.W., N. Munshi, K.C.A., P.G.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201242PMC
April 2017

Genomics of Multiple Myeloma.

J Clin Oncol 2017 Mar 13;35(9):963-967. Epub 2017 Feb 13.

Sebastien Robiou du Pont, Charlotte Fontan, Michel Attal, Jill Corre, and Hervé Avet-Loiseau, L'Institut Universitaire du Cancer Oncopole, Toulouse; Alice Cleynen, Centre National de la Recherche Scientifique, and Montpellier University, Montpellier, France; and Nikhil Munshi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.6705DOI Listing
March 2017

Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.

Am Soc Clin Oncol Educ Book 2016 ;35:e425-30

From the Laboratory for Genomics in Myeloma, Institut Universitaire du Cancer and University Hospital, Centre de Recherche en Cancerologie de Toulouse, Toulouse, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_159088
Publisher Site
http://dx.doi.org/10.1200/EDBK_159088DOI Listing
January 2017

Gene Expression Profiles in Myeloma: Ready for the Real World?

Clin Cancer Res 2016 Nov;22(22):5434-5442

Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0867DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546147PMC
November 2016

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

J Clin Oncol 2016 06 25;34(18):2125-32. Epub 2016 Apr 25.

Bruno Royer, Momar Diouf, and Jean Pierre Marolleau, University Hospital, Amiens; Stéphane Minvielle and Philippe Moreau, University Hospital; Stéphane Minvielle, Institut National de la Santé et de la Recherche Médicale U892, Nantes; Murielle Roussel and Hervé Avet-Loiseau, Institute Universitaire du Cancer de Toulouse Oncopole; Hervé Avet-Loiseau, University Hospital, Toulouse; Lionel Karlin, University Hospital, Lyon; Cyrille Hulin, University Hospital, Vandœuvre lès Nancy; Bertrand Arnulf, St Louis University Hospital; Laurent Frenzel, Necker University Hospital; Laurent Garderet, St Antoine University Hospital; Sylvain Choquet, La Pitié University Hospital, Paris; Margaret Macro, University Hospital, Caen; Sylvie Cailleres, General Hospital, Aix en Provence; Annie Brion, University Hospital, Besançon; Sabine Brechignac, University Hospital, Bobigny; Karim Belhadj, University Hospital, Creteil; Marie Lorraine Chretien, University Hospital, Dijon; Marc Wetterwald, General Hospital, Dunkerque; Carine Chaleteix, University Hospital, Clermont-Ferrand; Mourad Tiab, General Hospital, La Roche/Yon; Xavier Leleu, University Hospital, Poitiers; Jean Gabriel Fuzibet, University Department, Nice; Charles Dauriac, University Hospital, Rennes; Luc-Matthieu Forneker, University Hospital, Strasbourg; Lotfi Benboubker, University Hospital, Tours; and Thierry Facon, University Hospital, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1929DOI Listing
June 2016

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

Blood 2016 Feb 2;127(6):681-95. Epub 2015 Dec 2.

Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-646810DOI Listing
February 2016

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Haematologica 2015 Nov 23;100(11):e471-4. Epub 2015 Jul 23.

Immuno-Hematology, Saint-Louis Hospital, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Paris, France INSERM UMR 1126 Institut Universitaire d'Hématologie, Paris, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.127001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825293PMC
November 2015

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

J Clin Oncol 2015 Sep 3;33(26):2863-9. Epub 2015 Aug 3.

Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome, Rome; Elena Zamagni and Michele Cavo, Istituto di Ematologia Seragnoli, Università di Bologna, Bologna, Italy; Hervé Avet-Loiseau and Michel Attal, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse; Thierry Facon, Service des Maladies du Sang, Hôpital Claude Huriez, Centre Hospitalier Regionale et Universitaire Lille, Lille; Philippe Moreau, University Hospital Hotel-Dieu, Nantes, France; Henk M. Lokhorst, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC, Rotterdam, the Netherlands; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; Laura Rosinol, Hospital Clínic, Institut Clínic d'Investigacions Biomèdiques Ausgust Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jésus San Miguel, Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas, IDISNA, Pamplona, Spain; Paul Richardson and Kenneth C. Anderson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; Shaji Kumar and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA; Robert Z. Orlowski, The University of Texas MD Anderson Comprehensive Cancer Center, Houston, TX; Gareth Morgan, Myeloma Institutes for Research Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; Brian G.M. Durie, Cedars-Sinai Comprehensive Canc

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/08/03/JCO.2015.61
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.2267
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.2267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846284PMC
September 2015

Genetics of multiple myeloma: another heterogeneity level?

Blood 2015 Mar 27;125(12):1870-6. Epub 2015 Jan 27.

Unit for Genomics in Myeloma, L'Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France; Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale U1037, Toulouse, France;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-10-567370DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366624PMC
March 2015

Differential and limited expression of mutant alleles in multiple myeloma.

Blood 2014 Nov 18;124(20):3110-7. Epub 2014 Sep 18.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Hematology/Oncology, Boston Veterans Administration Healthcare System, West Roxbury, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-04-569327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231420PMC
November 2014

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

J Clin Oncol 2014 Sep 14;32(25):2712-7. Epub 2014 Jul 14.

Murielle Roussel, Valérie Lauwers-Cances, Catherine Gentil, Anne Huynh, Benjamin Hebraud, Jill Corre, and Hervé Avet-Loiseau, Hopitaux de Toulouse; Michel Attal, Institut Claudius Regaud, Toulouse; Nelly Robillard, Philippe Moreau, and Soraya Wuilleme, Hôtel Dieu, Nantes; Cyrille Hulin, Centre Hospitalier Brabois, Nancy; Xavier Leleu and Thierry Facon, Hôpital Claude Huriez, Lille; Lotfi Benboubker, Hôpital Bretonneau, Tours; Gérald Marit, Hôpital Haut-Lévêque, Bordeaux Pessac; Brigitte Pegourie, Hôpital Albert Michallon, Grenoble; Denis Caillot and Marie-Lorraine Chretien, Centre Hospitalier Le Bocage, Dijon; Christophe Fruchart, Centre François Baclesse, Caen; and Anne-Marie Stoppa, Institut Paoli Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/07/10/JCO.2013.54
Web Search
http://200.40.135.66:90/toc/0873/2014/0873-20140901-25-08.pd
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.8164
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.8164DOI Listing
September 2014

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

J Clin Oncol 2014 Jul 2;32(20):2173-80. Epub 2014 Jun 2.

Philippe Moreau, University Hospital Hôtel-Dieu; Jean-Luc Harousseau, Centre Rene Gauducheau, Nantes; Michel Attal, Centre Hospitalier Universitaire (CHU) Toulouse; Hervé Avet-Loiseau, CHU Rangueil, Toulouse; Gerald Marit, University Hospital of Bordeaux, Bordeaux; Cyrille Hulin, CHU Nancy, Nancy; Thierry Facon, Hopital Claude Huriez; Xavier Leleu, University Hospital of Lille, Lille; Denis Caillot, CHU Dijon, Dijon; Lotfi Benboubker, Centre Hospitalier Régional Universitaire Tours, Tours; Jean-Yves Mary, University Hospital Paris Saint-Louis, Paris, France; Michele Cavo, Annalisa Pezzi, and Elena Zamagni, Seràgnoli Institute of Hematology, Bologna; Antonio Palumbo, University of Torino, Torino; Maria Teresa Petrucci, Sapienza University of Rome, Rome; Francesca Patriarca, University Hospital, Udine, Italy; Pieter Sonneveld, Erasmus Medical Center, Rotterdam; Bronno van der Holt, Daniel den Hoed Cancer Center at Erasmus Medical Center, Rotterdam; Henk Lokhorst, University Medical Center Utrecht, Utrecht, the Netherlands; Hartmut Goldschmidt, Universitätsklinikum Heidelberg; Kai Neben, University of Heidelberg, Heidelberg, Germany; Laura Rosinol and Joan Bladé, Hospital Clinic, Barcelona; Juan Jose Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jesus san Miguel, University of Salamanca; Norma Gutierrez, Hospital Universitario de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879712PMC
July 2014

A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Clin Cancer Res 2014 Mar 27;20(5):1135-45. Epub 2013 Nov 27.

Authors' Affiliations: Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Bioinformatics and Computational Genomics Laboratory, Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada; Department of Computing Science, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Center for Cancer Systems Biology and Department of Genetics, Harvard Medical School, Boston University School of Medicine and Biomedical Engineering Department, Boston University, Boston, Massachusetts; Unité de Génomique du Myélome, Laboratoire UGM, University Hospital, CHU Rangueil, Toulouse, France; Hematology Laboratory, University Hospital; and INSERM U892, Nantes, France; Molecular Diagnostics Laboratory, Dana Farber Cancer Institute, Boston, Massachusetts; Biotique Systems Inc., www.biotiquesystems.com; Adult Leukemia Program, Dana Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0956DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4458245PMC
March 2014

The shaping and functional consequences of the dosage effect landscape in multiple myeloma.

BMC Genomics 2013 Oct 2;14:672. Epub 2013 Oct 2.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2164-14-672DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907079PMC
October 2013